Table 1 Baseline characteristics of NSTEACS patients in reloading P2Y12 receptor inhibitors and non-reloading P2Y12 inhibitors group
Reloading group (N = 1371) | Non-reloading group (N = 3419) | P value | |
|---|---|---|---|
Demographics | |||
Age, (years) | 64.33 ± 11.35 | 66.18 ± 11.48 | < 0.001 |
Male, n (%) | 946 (69.00) | 2290 (66.98) | 0.177 |
BMI, (kg/m2) | 24.49 ± 3.36 | 24.7 ± 3.53 | 0.101 |
Clinical history | |||
Previous MI | 336 (24.51) | 1125 (32.90) | < 0.001 |
Previous PCI | 389 (28.37) | 1310 (38.32) | < 0.001 |
Previous CABG | 19 (1.39) | 56 (1.64) | 0.525 |
Atrial fibrillation | 35 (2.55) | 146 (4.27) | 0.005 |
Chronic heart failure | 53 (3.87) | 282 (8.25) | < 0.001 |
Hypertension | 790 (57.62) | 2179 (63.73) | < 0.001 |
Diabetes mellitus | 361 (26.33) | 1066 (31.18) | < 0.001 |
Hyperlipemia | 224 (16.34) | 592 (17.32) | 0.416 |
Smoking | 364 (26.55) | 778 (22.76) | 0.005 |
Bleeding history | 14 (1.02) | 68 (2.06) | 0.014 |
Stroke/TIA | 114 (8.32) | 355 (10.38) | 0.030 |
Peripheral vascular disease | 28 (2.04) | 94 (2.75) | 0.160 |
COPD | 28 (2.04) | 71 (2.08) | 0.9398 |
Renal dysfunction | 26 (1.90) | 162 (4.74) | < 0.001 |
Presentation | |||
Cardiac shock | 3 (0.22) | 14 (0.41) | 0.316 |
Acute heart failure | 25 (1.82) | 107 (3.13) | 0.013 |
Cardiac arrest | 1 (0.07) | 7 (0.20) | 0.313 |
GRACE score | 126.98 ± 40.73 | 125.67 ± 40.96 | < 0.001 |
Killip classification | < 0.001 | ||
I | 872 (63.60%) | 1763 (51.56%) | |
II | 312 (22.76%) | 1024 (29.95%) | |
III | 139 (10.14%) | 467 (13.66%) | |
IV | 48 (3.50%) | 165 (4.83%) | |
Laboratory examinations | |||
Platelet, (*109) | 203.6 ± 67.04 | 206.8 ± 64.85 | 0.131 |
Creatinine, (umol/l) | 98.6 ± 86.8 | 93.35 ± 80.89 | 0.060 |
Hemoglobin, (g/l) | 122.5 ± 11.08 | 123.5 ± 12.38 | 0.016 |
NT-proBNP, (pg/ml) | 1786.12 ± 4006.99 | 2158.66 ± 4933.15 | 0.072 |
Medications | |||
Previous aspirin use | 1094 (79.80) | 2892 (84.59) | < 0.001 |
Reloading aspirin | 898 (65.50) | 104 (3.04) | < 0.001 |
Proton pump inhibitor | 764 (55.73) | 1640 (49.68) | < 0.001 |
GP IIb/IIIa | 170 (12.40) | 310 (9.07) | < 0.001 |
Operative treatment | |||
Thrombolysis | 1 (1.92) | 2 (2.13) | 0.9335 |
Coronary artery angiography | 1013 (73.89) | 2088 (63.25) | < 0.001 |
Three-vessel disease | 352(25.67%) | 634(18.54%) | < 0.001 |
Left main disease | 97 (7.08%) | 241 (7.05) | 0.974 |
PCI | 829 (60.47) | 1669 (48.82) | < 0.001 |
CABG | 9 (0.66) | 9 (0.66) | 0.773 |
Any Coagulant | 845 (61.63) | 1627 (47.59) | < 0.001 |
Warfarin | 9 (0.66) | 27 (0.79) | 0.629 |
Heparin | 45 (5.33) | 68 (4.18) | 0.196 |
LMWH | 787 (93.14) | 1458 (89.61) | 0.004 |
Bivalirudin | 4 (0.29) | 16 (0.47) | 0.393 |
Fondaparinux | 11 (1.30) | 46 (2.83) | 0.017 |
LVEF | 58.46 ± 9.97 | 57.92 ± 10.09 | 0.141 |